

Study Number: I20263
Test Type: TOX
Route: Dosing in Feed
Species/Strain: Rat/Harlan Sprague Dawley

PA18: Incidence Rates of Non-Neoplastic Lesions by Anatomic Site with Average Severity Grades

Test Compound: Tris (chloropropyl) phosphate

CAS Number: 13674-84-5

Final

Date Report Requested: 09/12/2024

Time Report Requested: 16:34:40

Lab: Burleson Research Technologies

Study Number: I20263
Study Gender: Both
PWG Approval Date: See web page for date of PWG Approval
Version: v1.7.0

Study Number: I20263

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

PA18: Incidence Rates of Non-Neoplastic Lesions by Anatomic Site with Average Severity Grades

Test Compound: Tris (chloropropyl) phosphate

CAS Number: 13674-84-5

Final

Date Report Requested: 09/12/2024

Time Report Requested: 16:34:40

Lab: Burleson Research Technologies

F1 Male: Immunopath

Treatment Groups (ppm)

	0	2500	5000	10000
Disposition Summary				
Animals Initially In Study	12	12	12	11
Censored				
Early Deaths				
Survivors				
Scheduled Sacrifice, Terminal	12	12	12	11
Number Animals Examined Microscopically	12	12	12	11
ALIMENTARY SYSTEM				
No Tissues/Organs Examined				
CARDIOVASCULAR SYSTEM				
No Tissues/Organs Examined				
ENDOCRINE SYSTEM				
ADRENAL GLAND	(12)	(12)	(12)	(11)
CORTEX; VACUOLATION; DIFFUSE	1 [1.0]	3 [1.0]	1 [1.0]	
GENERAL BODY SYSTEM				
No Tissues/Organs Examined				
HEMATOPOIETIC SYSTEM				
BONE MARROW	(12)	(12)	(12)	(11)
MYELOID CELL; NUMBER INCREASED				1 [1.0]

Study Number: I20263

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

PA18: Incidence Rates of Non-Neoplastic Lesions by Anatomic Site with Average Severity Grades

Test Compound: Tris (chloropropyl) phosphate

CAS Number: 13674-84-5

Final

Date Report Requested: 09/12/2024

Time Report Requested: 16:34:40

Lab: Burlinson Research Technologies

F1 Male: Immunopath

	Treatment Groups (ppm)			
	0	2500	5000	10000
HEPATOBIILIARY SYSTEM				
LIVER	(12)	(12)	(12)	(11)
EOSINOPHILIC FOCUS				1
EXTRAMEDULLARY HEMATOPOIESIS	3 [1.0]	5 [1.2]	9 [1.0]	
SUBCAPSULAR; FIBROSIS; FOCAL			1 [1.0]	
HEPATODIAPHRAGMATIC NODULE		2	1	
BILE DUCT; HYPERPLASIA		2 [1.0]	9 [1.1]	11 [1.8]
INFILTRATION CELLULAR; MIXED	11 [1.0]	8 [1.1]	12 [1.1]	10 [1.5]
IMMUNE SYSTEM				
BALT	(12)	(12)	(12)	(11)
LYMPH NODE	(0)	(1)	(0)	(0)
MESENTERIC, SINUS, PIGMENTED MACROPHAGE; NUMBER INCREASED		1 [1.0]		
LYMPH NODE, MESENTERIC	(12)	(12)	(12)	(11)
SINUS; ERYTHROPHAGOCYTOSIS		1 [1.0]		
SINUS ERYTHROCYTOSIS		1 [2.0]		
LYMPH NODE, POPLITEAL	(12)	(11)	(12)	(11)
PIGMENT	7 [1.0]	10 [1.0]	6 [1.0]	7 [1.0]
SPLEEN	(12)	(12)	(12)	(11)
ACCESSORY SPLEEN			1	
THYMUS	(12)	(12)	(12)	(11)
INTEGUMENTARY SYSTEM				
No Tissues/Organs Examined				
MUSCULOSKELETAL SYSTEM				
BONE	(12)	(12)	(12)	(11)
NERVOUS SYSTEM				
No Tissues/Organs Examined				

Study Number: I20263

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

PA18: Incidence Rates of Non-Neoplastic Lesions by Anatomic Site with Average Severity Grades

Test Compound: Tris (chloropropyl) phosphate

CAS Number: 13674-84-5

Final

Date Report Requested: 09/12/2024

Time Report Requested: 16:34:40

Lab: Burleson Research Technologies

F1 Male: Immunopath

Treatment Groups (ppm)

	0	2500	5000	10000
REPRODUCTIVE SYSTEM				
No Tissues/Organs Examined				
RESPIRATORY SYSTEM				
LUNG	(12)	(12)	(12)	(11)
ALVEOLUS; INFILTRATION CELLULAR; HISTIOCYTE	7 [1.3]	5 [1.0]	7 [1.0]	6 [1.3]
SPECIAL SENSES SYSTEM				
No Tissues/Organs Examined				
URINARY SYSTEM				
KIDNEY	(12)	(12)	(12)	(11)
RENAL TUBULE; CAST; HYALINE	6 [1.3]	6 [1.0]	1 [1.0]	3 [1.0]
CHRONIC PROGRESSIVE NEPHROPATHY	5 [1.0]	2 [1.0]	5 [1.2]	3 [1.3]
PELVIS; DILATION				2 [2.0]
FIBROSIS				1 [2.0]
UROTHELIUM; HYPERPLASIA				1 [2.0]
INTERSTITIUM; INFILTRATION CELLULAR; LYMPHOHISTIOCYTIC			1 [1.0]	1 [1.0]
PELVIS; INFLAMMATION; CHRONIC-ACTIVE				1 [2.5]
URINARY BLADDER	(0)	(0)	(0)	(1)
CALCULUS				1
DILATION				1 [3.0]
UROTHELIUM; HYPERPLASIA				1 [4.0]
MUCOSA; INFLAMMATION; CHRONIC-ACTIVE				1 [2.0]

Study Number: I20263

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

PA18: Incidence Rates of Non-Neoplastic Lesions by Anatomic Site with Average Severity Grades

Test Compound: Tris (chloropropyl) phosphate

CAS Number: 13674-84-5

Final

Date Report Requested: 09/12/2024

Time Report Requested: 16:34:40

Lab: Burleson Research Technologies

F1 Female: Immunopath

	Treatment Groups (ppm)			
	0	2500	5000	10000
Disposition Summary				
Animals Initially In Study	12	12	12	11
Censored		1		
Early Deaths				
Survivors				
Scheduled Sacrifice, Terminal	12	11	12	11
Number Animals Examined Microscopically	12	11	12	11
ALIMENTARY SYSTEM				
No Tissues/Organs Examined				
CARDIOVASCULAR SYSTEM				
No Tissues/Organs Examined				
ENDOCRINE SYSTEM				
ADRENAL GLAND	(12)	(11)	(12)	(11)
ACCESSORY ADRENOCORTICAL NODULE	2	1	1	1
CORTEX; HYPERTROPHY; FOCAL	2 [1.0]			
CORTEX; VACUOLATION; DIFFUSE				1 [1.0]
GENERAL BODY SYSTEM				
No Tissues/Organs Examined				
HEMATOPOIETIC SYSTEM				
BONE MARROW	(12)	(11)	(12)	(11)

Study Number: I20263

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

PA18: Incidence Rates of Non-Neoplastic Lesions by Anatomic Site with Average Severity Grades

Test Compound: Tris (chloropropyl) phosphate

CAS Number: 13674-84-5

Final

Date Report Requested: 09/12/2024

Time Report Requested: 16:34:40

Lab: Burleson Research Technologies

F1 Female: Immunopath

	Treatment Groups (ppm)			
	0	2500	5000	10000
HEPATOBIILIARY SYSTEM				
LIVER	(12)	(11)	(12)	(11)
EOSINOPHILIC FOCUS		1		
EXTRAMEDULLARY HEMATOPOIESIS	3 [1.0]		5 [1.0]	6 [1.0]
HEPATODIAPHRAGMATIC NODULE	1			
BILE DUCT; HYPERPLASIA	1 [1.0]		4 [1.0]	10 [1.0]
INFILTRATION CELLULAR; MIXED	11 [1.2]	11 [1.0]	11 [1.0]	9 [1.0]
IMMUNE SYSTEM				
BALT	(12)	(11)	(11)	(11)
LYMPH NODE, MESENTERIC	(12)	(11)	(12)	(11)
SINUS; ERYTHROPHAGOCYTOSIS	1 [1.0]			
SINUS, MACROPHAGE; PIGMENT	1 [1.0]			
SINUS ERYTHROCYTOSIS	1 [1.0]			
LYMPH NODE, POPLITEAL	(11)	(11)	(12)	(10)
PIGMENT	8 [1.0]	6 [1.0]	7 [1.0]	4 [1.0]
SPLEEN	(12)	(11)	(12)	(11)
ACCESSORY SPLEEN			1	1
THYMUS	(12)	(11)	(12)	(11)
INTEGUMENTARY SYSTEM				
No Tissues/Organs Examined				
MUSCULOSKELETAL SYSTEM				
BONE	(12)	(11)	(11)	(11)
NERVOUS SYSTEM				
No Tissues/Organs Examined				
REPRODUCTIVE SYSTEM				
No Tissues/Organs Examined				

Study Number: I20263

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

PA18: Incidence Rates of Non-Neoplastic Lesions by Anatomic Site with Average Severity Grades

Test Compound: Tris (chloropropyl) phosphate

CAS Number: 13674-84-5

Final

Date Report Requested: 09/12/2024

Time Report Requested: 16:34:40

Lab: Burleson Research Technologies

F1 Female: Immunopath

	Treatment Groups (ppm)			
	0	2500	5000	10000
RESPIRATORY SYSTEM				
LUNG	(12)	(11)	(12)	(11)
ALVEOLUS; INFILTRATION CELLULAR; HISTIOCYTE	9 [1.0]	8 [1.0]	10 [1.0]	9 [1.0]
INTERSTITIUM; INFILTRATION CELLULAR; MIXED		1 [1.0]		
SPECIAL SENSES SYSTEM				
No Tissues/Organs Examined				
URINARY SYSTEM				
KIDNEY	(12)	(11)	(12)	(11)
RENAL TUBULE; CAST; HYALINE	2 [1.0]	1 [1.0]		
CHRONIC PROGRESSIVE NEPHROPATHY	3 [1.0]	4 [1.0]	2 [1.0]	1 [1.0]
INTERSTITIUM; INFILTRATION CELLULAR; LYMPHOHISTIOCYTIC	1 [1.0]	3 [1.0]	1 [1.0]	1 [1.0]
INFILTRATION CELLULAR; LYMPHOHISTIOCYTIC			1 [1.0]	

Study Number: I20263

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

PA18: Incidence Rates of Non-Neoplastic Lesions by Anatomic Site with Average Severity Grades

Test Compound: Tris (chloropropyl) phosphate

CAS Number: 13674-84-5

Final

Date Report Requested: 09/12/2024

Time Report Requested: 16:34:40

Lab: Burleson Research Technologies

LEGEND

For this study, "Censored" refers to one female in the 2500 ppm group that was euthanized because it escaped from the cage.

Number of animals examined given for each tissue. If none of the animals examined have the specific lesion then there is a blank for that dose group for that specific lesion. Mean severity grade denoted by 1 - minimal, 2 - mild, 3 - moderate, 4 - marked.

Number of animals with observation reported with mean severity grade in square brackets

**** END OF REPORT ****